Bellevue Healthcare Strategy (Lux)

 Investments in the 40 most attractive healthcare stocks worldwide, regionally diversified and across sub sectors

 Profiting from pent-up demand in Emerging Markets as well as from innovation in industrialized countries 

Strong focus on quality mid caps and underweight in pharma stocks 

Please select a share class.

Please find a more detailed description of share classes here.

Investment Focus

ISIN-No. LU1477742818

The Bellevue Healthcare Strategy Fund invests in global healthcare companies with innovative business models. Its investment universe consists of biotechnology and pharma companies, medical technology and services companies as well as generics producers that are involved in the development, manufacturing or sale of products and services.

Indexed performance (as at: 27.01.2022)

NAV: USD 241.75 (26.01.2022)

Fonds (Brutto)
01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display

Rolling performance (26.01.2022)

26.01.2021 - 26.01.2022-7.61%3.98%
26.01.2020 - 26.01.202127.99%16.87%
26.01.2019 - 26.01.202017.22%20.70%
26.01.2018 - 26.01.2019-3.23%-1.34%

Annualized performance (26.01.2022)

1 year-7.61%3.98%
3 years11.33%13.53%
5 years13.30%13.00%
Since Inception p.a.13.41%12.92%

Cumulative performance (26.01.2022)

1 year-7.61%3.98%
3 years38.08%46.42%
5 years86.79%84.29%
Since Inception93.40%89.03%

Annual performance


Investment Focus

The Bellevue Healthcare Strategy Fund invests in global healthcare companies with innovative business models. Its investment universe consists of biotechnology and pharma companies, medical technology and services companies as well as generics producers that are involved in the development, manufacturing or sale of products and services. Experienced sector specialists focus on profitable companies that have a well-established product portfolio. The fund invests top down in the four regions North America, Western Europe, Emerging Markets and Japan/Oceania. For each of these regions, the most attractive companies are determined based on quantitative and qualitative criteria. The fund seeks to outperform the MSCI World Healthcare Index. Show moreShow less

Investment suitability & Risk


Low risk

High risk

The Fund’s investment objective is to generate attractive and competitive long-term capital growth. It is particularly suited to investors with an investment horizon of at least 5 years. The Fund is exposed to the risks typical of equity investments.

General Information

Investment ManagerBellevue Asset Management AG
CustodianRBC Investor Services, Luxembourg
Fund AdministratorRBC Investor Services, Luxembourg
Launch date31.10.2016
Year end closing30. Jun
NAV CalculationDaily "Forward Pricing"
Cut of time15:00 CET
Management Fee0.90%
Subscription Fee (max.)5.00%
ISIN numberLU1477742818
Valor number33635311
Total expense ratio (TER)1.50% (31.12.2021)

Legal Information

Legal formSICAV Luxembourg jurisdiction
SFDR categoryArticle 8

Top 10 positions

Vertex Pharmaceut.
Regeneron Pharma.
HCA Holdings
Molina Healthcare
Halozyme Therapeutics
Horizon Therapeutics

Breakdown by sector





  • The fund invests in the 40 most attractive healthcare stocks worldwide.
  • Proprietary investment process: Half-yearly company evaluation and rebalancing.
  • Underweighting of pharma and US stocks against the relevant healthcare indices.
  • Strong focus on quality mid-caps.
  • Bellevue - Healthcare pioneer since 1993 and today one of the biggest independent investors in the sector in Europe.


  • Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
  • The fund may invest in financial instruments that might have a rather low level of liquidity, which can in turn affect the fund’s liquidity.
  • Investments in foreign currencies are subject to currency risks.
  • Investing in emerging markets entails the additional risk of political and social instability.
  • Increased opportunities through possible derivative transactions are accompanied by an increased risk of losses.

December 2021 was another strong month for the stock market as a whole. The global MSCI World Index advanced 3.3% (in CHF) and the MSCI World Healthcare Index closed the month with an even better gain of 6.3%. The Bellevue Healthcare Strategy Fund (Lux) was unable to match their performance, but it still delivered a positive return of 2.1% (I shares). Market moves within the healthcare sector during the month of December resembled the patterns that had already been observed throughout the second half of 2021: Buying activity was clearly focused on the US market. The US companies in the fund’s portfolio thus made strong gains in December: The ten US stocks in the portfolio, which have an aggregate weighting of 35.8%, delivered a consolidated performance of 9.2% and contributed 3.3%-points to the fund's overall monthly performance. More than 70% of the stocks in the fund's benchmark, the MSCI World Healthcare Index, are US stocks, and that explains the fund's relative underperformance in December. The fact that congressional Democrats were unable to secure passage of the Build Back Better Act as planned in December gave drug maker stocks a big boost, because this also took any government drug pricing reforms off the table for now. The US biotech company Vertex Pharmaceuticals (+16.3%) got an extra boost from the positive data it presented from its Phase II trial of VX-147 in its APOL1 program, which represents a new option for the treatment of focal segmental glomerulosclerosis (FSGS). Familial FSGS is a rare form of kidney disease in children and adults. Shares of Halozyme Therapeutics (+21.1%) were marked up after the US company announced a share buyback program. Shares of Wuxi Biologics lost ground (-13.7%) after the Financial Times published an article claiming that the US government was about to add Chinese biotech firms to its list of sanctioned corporations. That ultimately turned out to be nothing more than a rumor. The US government’s subsequently updated blacklist did not include any Chinese companies from the healthcare sector.

The investment process for the Bellevue Healthcare Strategy Fund resembles the rules-based investment process that Bellevue has successfully applied since 2007. In this approach, the 40 most attractive stocks in the healthcare sector worldwide are selected every six months. The Bellevue Healthcare Team screens about 600 of the 4000 listed companies in the healthcare sector worldwide based on four quantitative criteria (PEG valuation, price/sales, sales growth and EBITDA/sales) and four qualitative criteria (assessing the company's management, product pipeline, operating risks and country-related risks). The ten most promising stocks from four different regions – Western Europe, North America, Japan/Australia and emerging markets – are selected. The maximum weighting of the region with the highest overall score, which is usually North America, is capped at 35% during the periodic rebalancing, which increases the emphasis given to emerging markets. Companies with rich valuations and low growth rates will rarely be selected for the portfolio. Mid cap stocks have typically represented 60-80% and the Asia region approximately one-third of the portfolio. Pharmaceutical stocks are clearly underweighted compared to the MSCI World Healthcare Index. Bellevue has applied this investment approach since April of 2007 and it is used to compile the Adamant Global Healthcare Index.

Past performance is not a reliable indicator of future results and can be misleading. As the sub-fund is denominated in a currency that may differ than an investor’s base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a sub-fund, thus the performance of a benchmark is not a reliable indicator of future performance of the sub-fund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred. All figures in base currency in %, calculated by the total return / BVI method.Show moreShow less


  • Portfolio Manager

    Samuel Stursberg

    After receiving his Master of Science in Biochemistry from the University of Basel and a degree in Economics from the University of St. Gallen (lic. oec. HSG), Samuel Stursberg conducted stock analysis at Bank Sarasin among others and was Head Research at Adamant Biomedical Investments AG before joining Bellevue Asset Management as Head Research health Care Funds & Mandates in 2015.
  • Portfolio Manager

    Zahide Donat

    Joined Bellevue in 2015 as Portfolio Manager. Prior to joining Bellevue she spent one year at Credit Suisse AG as banking operations specialist and from 2010 to 2013 as client advisor in the customer center (e-banking Hotline, as of 2012 also Service Line) at Migros Bank AG.
  • Portfolio Manager

    Cyrill Zimmermann

    Dr. Cyrill Zimmerman is Head of Healthcare Funds & Mandates and a member of the Executive Board of Bellevue Asset Management. He founded Adamant Biomedical Investments in 2001 and managed the investment boutique until its acquisition by Bellevue in 2014. Cyrill Zimmerman holds a PhD from the University of Zurich.

These insights might interest you